Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Liquidia Corporation (NASDAQ:LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is manufactured by Sandoz Inc. (Sandoz) and was launched as the first-to-file, fully-substitutable generic treprostinil for parenteral administration in March 2019. Liquidia PAH, LLC (formerly known as RareGen), a wholly owned subsidiary of Liquidia (Liquidia PAH), partnered with Sandoz in August 2018 on an exclusive basis to market and commercialize Treprostinil Injection.
美國聯合醫療公司對液壓公司發起了干擾，導致通用曲前列他注射劑的推出造成了超過1.37億美元的損失。曲前列他注射劑由Sandoz公司生產，並在2019年3月作爲首次文件完全可替代的通用曲前列他注射劑上市用於經靜脈注射。液壓PAH有限責任公司（前身爲RareGen），作爲液壓公司的全資子公司，於2018年8月與Sandoz達成了獨家合作關係，以營銷和推廣曲前列他注射劑。
譯文內容由第三人軟體翻譯。